(CCEP) Coca-Cola European Partners - Ratings and Ratios
Soft Drinks, Water, Juice, Energy Drink, Tea
Dividends
| Dividend Yield | 2.57% |
| Yield on Cost 5y | 5.79% |
| Yield CAGR 5y | 20.81% |
| Payout Consistency | 94.0% |
| Payout Ratio | 69.3% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 18.3% |
| Value at Risk 5%th | 29.2% |
| Relative Tail Risk | -2.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.78 |
| Alpha | 12.75 |
| CAGR/Max DD | 1.57 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.330 |
| Beta | 0.211 |
| Beta Downside | 0.432 |
| Drawdowns 3y | |
|---|---|
| Max DD | 14.35% |
| Mean DD | 3.86% |
| Median DD | 3.00% |
Description: CCEP Coca-Cola European Partners December 04, 2025
Coca-Cola Europacific Partners PLC (NASDAQ: CCEP) is a leading bottler that produces, distributes, and sells a broad portfolio of non-alcoholic ready-to-drink beverages, ranging from classic sodas (Coca-Cola, Sprite, Fanta) and low-/no-sugar variants to water, sports drinks, teas, coffees, juices, and energy drinks such as Monster and Reign. The company also bottles and markets licensed spirits-based RTD products (e.g., Absolut Vodka & Sprite, Bacardi Mixed with Coca-Cola).
Founded in 1904 and headquartered in Uxbridge, United Kingdom, the firm rebranded from Coca-Cola European Partners to Coca-Cola Europacific Partners in May 2021 after merging its European and Pacific bottling operations. It trades as a common stock under the ticker CCEP and sits in the GICS sub-industry “Soft Drinks & Non-alcoholic Beverages.”
Key performance indicators from FY 2023 show net revenue of approximately $27.5 billion, an adjusted EBITDA margin near 15 % and a cash-conversion rate above 80 %, supporting a dividend yield of roughly 2.8 % and a net-debt-to-EBITDA leverage of ~2.0×. Volume growth was modest (+2 % YoY) as the company continued to shift sales toward low-sugar and premium offerings.
Sector-level drivers that materially affect CCEP include rising commodity costs (sugar, aluminum), evolving consumer preferences toward healthier and functional drinks, and regulatory pressures such as sugar taxes across Europe. The firm’s extensive distribution network and strong brand licensing agreements provide a defensive moat in a market where brand equity remains a primary source of pricing power.
For a deeper quantitative breakdown, the ValueRay platform offers a granular view of CCEP’s financial ratios and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (3.15b TTM) > 0 and > 6% of Revenue (6% = 2.40b TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 8.38pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -4.02% (prev -4.84%; Δ 0.82pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 5.55b > Net Income 3.15b (YES >=105%, WARN >=100%) |
| Net Debt (10.35b) to EBITDA (6.43b) ratio: 1.61 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (459.0m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 35.88% (prev 36.21%; Δ -0.33pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 130.0% (prev 90.70%; Δ 39.33pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 11.13 (EBITDA TTM 6.43b / Interest Expense TTM 438.4m) >= 6 (WARN >= 3) |
Altman Z'' 2.00
| (A) -0.05 = (Total Current Assets 8.08b - Total Current Liabilities 9.69b) / Total Assets 31.79b |
| (B) 0.28 = Retained Earnings (Balance) 8.95b / Total Assets 31.79b |
| (C) 0.16 = EBIT TTM 4.88b / Avg Total Assets 30.79b |
| (D) 0.33 = Book Value of Equity 7.72b / Total Liabilities 23.28b |
| Total Rating: 2.00 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.00
| 1. Piotroski 6.50pt |
| 2. FCF Yield 8.88% |
| 3. FCF Margin 10.00% |
| 4. Debt/Equity 1.50 |
| 5. Debt/Ebitda 1.61 |
| 6. ROIC - WACC (= 13.62)% |
| 7. RoE 38.11% |
| 8. Rev. Trend 62.29% |
| 9. EPS Trend -6.78% |
What is the price of CCEP shares?
Over the past week, the price has changed by -1.13%, over one month by +4.42%, over three months by +3.61% and over the past year by +18.69%.
Is CCEP a buy, sell or hold?
- Strong Buy: 7
- Buy: 2
- Hold: 4
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the CCEP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 95.4 | 5.2% |
| Analysts Target Price | 95.4 | 5.2% |
| ValueRay Target Price | 110.8 | 22.2% |
CCEP Fundamental Data Overview November 25, 2025
P/E Trailing = 23.557
P/E Forward = 17.9211
P/S = 1.9595
P/B = 4.4174
P/EG = 1.4799
Beta = 0.383
Revenue TTM = 40.04b EUR
EBIT TTM = 4.88b EUR
EBITDA TTM = 6.43b EUR
Long Term Debt = 9.22b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.26b EUR (from shortTermDebt, last quarter)
Debt = 12.01b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.35b EUR (from netDebt column, last quarter)
Enterprise Value = 45.10b EUR (35.15b + Debt 12.01b - CCE 2.06b)
Interest Coverage Ratio = 11.13 (Ebit TTM 4.88b / Interest Expense TTM 438.4m)
FCF Yield = 8.88% (FCF TTM 4.00b / Enterprise Value 45.10b)
FCF Margin = 10.00% (FCF TTM 4.00b / Revenue TTM 40.04b)
Net Margin = 7.86% (Net Income TTM 3.15b / Revenue TTM 40.04b)
Gross Margin = 35.88% ((Revenue TTM 40.04b - Cost of Revenue TTM 25.67b) / Revenue TTM)
Gross Margin QoQ = 35.34% (prev 35.58%)
Tobins Q-Ratio = 1.42 (Enterprise Value 45.10b / Total Assets 31.79b)
Interest Expense / Debt = 0.82% (Interest Expense 98.0m / Debt 12.01b)
Taxrate = 25.63% (323.0m / 1.26b)
NOPAT = 3.63b (EBIT 4.88b * (1 - 25.63%))
Current Ratio = 0.83 (Total Current Assets 8.08b / Total Current Liabilities 9.69b)
Debt / Equity = 1.50 (Debt 12.01b / totalStockholderEquity, last quarter 8.03b)
Debt / EBITDA = 1.61 (Net Debt 10.35b / EBITDA 6.43b)
Debt / FCF = 2.59 (Net Debt 10.35b / FCF TTM 4.00b)
Total Stockholder Equity = 8.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.90% (Net Income 3.15b / Total Assets 31.79b)
RoE = 38.11% (Net Income TTM 3.15b / Total Stockholder Equity 8.25b)
RoCE = 27.93% (EBIT 4.88b / Capital Employed (Equity 8.25b + L.T.Debt 9.22b))
RoIC = 18.83% (NOPAT 3.63b / Invested Capital 19.27b)
WACC = 5.22% (E(35.15b)/V(47.16b) * Re(6.79%) + D(12.01b)/V(47.16b) * Rd(0.82%) * (1-Tc(0.26)))
Discount Rate = 6.79% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.11%
[DCF Debug] Terminal Value 77.02% ; FCFE base≈2.90b ; Y1≈2.67b ; Y5≈2.40b
Fair Price DCF = 96.07 (DCF Value 43.23b / Shares Outstanding 450.0m; 5y FCF grow -9.98% → 3.0% )
EPS Correlation: -6.78 | EPS CAGR: -46.32% | SUE: 0.0 | # QB: 0
Revenue Correlation: 62.29 | Revenue CAGR: 19.15% | SUE: 2.21 | # QB: 1
EPS next Year (2026-12-31): EPS=4.45 | Chg30d=+0.002 | Revisions Net=+0 | Growth EPS=+8.9% | Growth Revenue=+2.7%
Additional Sources for CCEP Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle